Eli Lilly

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross domestic product. McKinsey & Co. follows suit, noting AI could generate 30% efficiency gains and cost savings in the pharmaceutical sector and trigger financial gains of up to $110 billion annually.

A little over a year ago, a Renton man was told there was only one thing left to decide. Did he want to die at home, or in the hospital? He's still living.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases offering training for it.

Telescope Innovations Corp. (CSE:TELI) is leveraging its expertise to advance chemistry process development and crystallization optimization in pharmaceuticals, industrial chemicals, and critical minerals ・Telescope's Self-Driving Labs (SDLs) integrate AI,

We recently published a list of 35 Non-Tech AI Opportunities Amid DeepSeek Selloff. In this article, we are going to take a look at where IQVIA Holdings Inc. (NYSE:IQV) stands against other non-tech AI opportunities amid DeepSeek selloff.